<DOC>
	<DOCNO>NCT01442675</DOCNO>
	<brief_summary>The purpose trial describe safety antibody response revaccination Menactra vaccine person receive first dose ≥11 year age . Primary Objective : - To evaluate antibody response meningococcal serogroups A , C , Y , W-135 , measure serum bactericidal assay use human complement ( SBA-HC ) , induced Menactra vaccine subject first vaccinate Menactra 4-6 year ago . Secondary Objective : - To evaluate antibody response serogroups A , C , Y , W-135 serum specimen collect 6 day post-vaccination subset study population . Observational Objective : - To describe rate immediate reaction , solicit injection-site systemic reaction , unsolicited adverse event serious adverse event follow vaccination .</brief_summary>
	<brief_title>Study Single Dose Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine</brief_title>
	<detailed_description>All participant receive one dose Menactra vaccine first clinic visit . There telephone safety follow-up contact six month post-vaccination .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Received Menactra 4 6 year prior enrollment , age ≥11 year , &lt; 56 year age day enrollment . Informed consent form sign date subject subject parent ( ) another legally acceptable representative ( independent witness require local regulation ) . Able attend schedule visit comply trial procedure . Subject pregnant , lactating , child bear potential without use effective method contraception practice abstinence least 4 week prior vaccination least 4 week vaccination . Females premenarche postmenopausal least 1 year , surgically sterile exclude . Any condition , opinion Investigator , would pose health risk participant interfere evaluation vaccine . Chronic illness , opinion Investigator , stage might interfere trial conduct completion . History document invasive meningococcal disease . Participation another interventional clinical trial investigate vaccine , drug , medical device , medical procedure 30 day precede first study vaccination course study , unless intervention study occur within 30 day prior first study vaccination none plan subject would complete safety surveillance present study . Suspected known hypersensitivity latex component Menactra vaccine , history lifethreatening reaction Menactra vaccine vaccine contain substance . Receipt meningococcal vaccine since receipt single dose Menactra vaccine 46 year prior enrollment . Receipt vaccine within 30 day receive study vaccine , plan receive another vaccine Day 28 visit ; except influenza vaccine may receive 30 15 day ( less 15 day ) receive study vaccine . Receipt immune globulin , blood bloodderived product past 3 month . Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede six month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) . History laboratoryconfirmed seropositivity Human Immunodeficiency Virus ( HIV ) , Hepatitis B , Hepatitis C , report subject . Personal history GuillainBarré syndrome ( GBS ) . Laboratoryconfirmed thrombocytopenia , may contraindication IM vaccination , discretion Investigator . Bleeding disorder receipt anticoagulants 3 week precede inclusion , may contraindication intramuscular ( IM ) vaccination , discretion Investigator . Deprived freedom administrative court order , emergency setting , hospitalize involuntarily . Current alcohol drug use , opinion Investigator , might interfere ability comply trial procedure . Receipt oral injectable antibiotic therapy within 72 hour prior first blood draw . Moderate severe acute illness/infection ( accord Investigator judgment ) febrile illness ( temperature ≥ 38.0°C [ ≥ 100.4°F ] ) day vaccination . A prospective subject enrol study condition resolve febrile event subside . Identified Investigator employee Investigator study center direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Infection</keyword>
	<keyword>Menactra®</keyword>
</DOC>